Clinical Trial Update: A Study to Evaluate the Effects of Azilsartan on Coronary Artery Plaque in Essential Hypertensive Patients With Stable Angina and Dyslipidemia. [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating azilsartan on coronary artery plaque in patients with essential hypertension, stable angina, and dyslipidemia has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemia
• Essential Hypertension
• Stable Angina

Drugs mentioned

• Azilsartan (azilsartan)

Snippet

Sponsor: Takeda | Conditions: Essential Hypertension With Stable Angina and Dyslipidemia | Phase 4 | Status: WITHDRAWN